Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

CEA of SGLT2 Inhibitors in Gout Flares and Related ED Visits, Hospitalizations

In patients with gout, initiation of treatment with sodium–glucose cotransporter-2 inhibitors (SGLT2is) for diabetes may reduce recurrent flares; reduce gout-primary emergency department (ED) visits and hospitalizations; and prevent major cardiovascular events, researchers report. “Given the pleiotropic cardiometabolic benefits associated with SGLT2is among patients with type 2 diabetes, this class of medications may be a particularly attractive addition to our current urate-lowering therapies to simultaneously address the high burden of gout and cardiometabolic sequelae,” conclude the authors.

Patients included in the propensity score–matched cohort study had both type 2 diabetes and gout and initiated SGLT2is or dipeptidyl peptidase 4 inhibitors (DPP-4is) during the 2014–22 period. The investigators looked for ED visits, hospitalizations, outpatient visits, and medication dispensing records in a general population database.

With a primary outcome of recurrent gout flare counts and several secondary outcomes, the study showed: “After propensity score matching, the flare rate was lower among SGLT2i initiators than DPP-4is initiators (52.4 and 79.7 events per 1000 person-years, respectively), with a rate ratio (RR) of 0.66 (95% CI, 0.57 to 0.75) and a rate difference (RD) of −27.4 (CI, −36.0 to −18.7) per 1000 person-years. The corresponding RR and RD for gout-primary ED visits and hospitalizations were 0.52 (CI, 0.32 to 0.84) and −3.4 (CI, −5.8 to −0.9) per 1000 person-years, respectively. The corresponding hazard ratio (HR) and RD for myocardial infarction were 0.69 (CI, 0.54 to 0.88) and −7.6 (CI, −12.4 to −2.8) per 1000 person-years; the HR for stroke was 0.81 (CI, 0.62 to 1.05). Those who initiated SGLT2is showed higher risk for [the postive control] genital infection (HR, 2.15 [CI, 1.39 to 3.30]) and no altered risk for [the negative control] osteoarthritis encounter (HR, 1.07 [CI, 0.95 to 1.20]). Results were similar when propensity score overlap weighting was applied.”

Source: Annals of Internal Medicine